LBL Biotech

LBL Biotech is at the forefront of biotechnology research, dedicated to advancing the science of protein therapy. With a focus on innovative solutions, LBL Biotech is developing a combination therapy treatment targeting pancreatic cancer. Their proprietary technology combines an IL-20 antibody with an immune checkpoint PD-1 antibody to attenuate tumors, demonstrating excellent efficacy in treating a range of conditions. LBL Biotech is located in Taiwan.

LBL Biotech's commitment to cutting-edge research and development positions them as a key player in the biotechnology sector. The company's work in attenuating tumors and addressing challenging diseases reflects its dedication to improving patient outcomes and driving medical advancements. LBL Biotech's research holds promise for transforming the treatment landscape for various cancers and related conditions.

Located in Taiwan, LBL Biotech is poised for continued growth and success in the biotechnology industry. We invite the management of LBL Biotech to create a customized and exclusive company showcase and product listing on our platform to further enhance their visibility and commercial development.